Antibe Therapeutics Inc., of Toronto, said an article published in PLOS ONE described the ability of anti-inflammatory drug ATB-346 to prevent and reverse tumorigenesis in mice that carry the same genetic mutation, called APCmin, which is found in more than 80 percent of humans with colon cancer.